Land: Nederland
Taal: Nederlands
Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
LEVETIRACETAM 100 mg/ml
AMETAS medical GmbH Christophstrasse 6-8 09212 LIMBACH-OBERFROHNA (DUITSLAND)
LEVETIRACETAM 100 mg/ml
Drank
BANANENSMAAKSTOF ; CITROENZUUR 1-WATER (E 330) ; METHYLPARAHYDROXYBENZOAAT (E 218) ; NATRIUMCHLORIDE ; PROPYLPARAHYDROXYBENZOAAT ; SACCHAROIDE NATRIUM X-WATER (E 954) ; SORBITOL, VLOEIBAAR, NIET-KRISTALLISEERBAAR (E 420) ; TRINATRIUMCITRAAT 2-WATER (E 331) ; WATER, GEZUIVERD, BANANENSMAAKSTOF ; CITROENZUUR 1-WATER (E 330) ; METHYLPARAHYDROXYBENZOAAT (E 218) ; NATRIUMCHLORIDE ; PROPYLPARAHYDROXYBENZOAAT (E 216) ; SACCHAROIDE NATRIUM X-WATER (E 954) ; SORBITOL, VLOEIBAAR, NIET-KRISTALLISEERBAAR (E 420) ; TRINATRIUMCITRAAT 2-WATER (E 331) ; WATER, GEZUIVERD
Oraal gebruik
1900-01-01
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT LEVETIRACETAM AMETAS 100 MG/ML, DRANK Levetiracetam READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR CHILD START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Levetiracetam AMETAS is and what it is used for 2. What you need to know before you take Levetiracetam AMETAS 3. How to take Levetiracetam AMETAS 4. Possible side effects 5. How to store Levetiracetam AMETAS 6. Contents of the pack and other information 1. WHAT LEVETIRACETAM AMETAS IS AND WHAT IT IS USED FOR Levetiracetam is an antiepileptic medicine (a medicine used to treat seizures in epilepsy). Levetiracetam AMETAS is used: - on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy. Epilepsy is a condition where the patients have repeated fits (seizures). Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation). Levetiracetam has been given to you by your doctor to reduce the number of fits. - as an add-on to other antiepileptic medicines to treat: - partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age - myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy - primary generalised tonic-clonic seizures (major fits, inclu Lees het volledige document
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Levetiracetam AMETAS 100 mg/ml, Drank 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 100 mg levetiracetam Excipients with known effect: Each ml contains 1 mg of methyl parahydroxybenzoate (E218), 0.2 mg of propyl parahydroxybenzoate (E216), 0.02 mg benzyl alcohol (E1519), 2.9 mg propylene glycol (E1520) and 300 mg sorbitol liquid (non crystallising) (E420). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Oral solution. Clear liquid. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Levetiracetam AMETAS is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy. Levetiracetam AMETAS is indicated as adjunctive therapy • in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy. • in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. • in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Partial onset seizures_ The recommended dosing for monotherapy (from 16 years of age) and adjunctive therapy is the same; as outlined below. _All indications_ _Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more _ _ _ The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. However, a lower initial dose of 250 mg twice daily may be given based on physician assessment of seizure reduction versus potential side effects. This can be increased to 500 mg twice daily after two weeks. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can Lees het volledige document